Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $567 from $555 and keeps a Buy rating on the shares. After having ...

In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...

The Samsung Galaxy S25 Edge has appeared in a YouTube video showing off its slender build. The video features two dummy units of the device and compares them to the Galaxy S25 Ultra to help give ...

The global Tax Tech Market will grow from USD 18.53 billion in 2024 to USD 36.72 billion by 2030 at a compounded annual growth rate (CAGR) ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Google’s Gemini 2.5 Pro is available now in Google AI Studio and in the Gemini app for Gemini Advanced users, and will be coming to Vertex AI soon. But let’s be real—AI models are often ...

LAW FIRM PRESSURE CAMPAIGN HITS CONGRESS: President Donald Trump’s retribution tour against Big Law has arrived on Capitol Hill, Dasha Burns, Daniel and I report. An email circulated by a high ...

Vertex Ventures and Zigg Capital led the funding round, which brought the total Hakimo raised to $20.5 million. Hakimo stated the sum is powering the launch of AI Operator, a security product ...

Growth drivers for this segment include the increase in type 2 diabetes and obesity cases, a burgeoning demand for cutting-edge treatment alternatives, and progressive therapies that tackle both ...